Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KMDANASDAQ:KZRNASDAQ:ORMPNASDAQ:TFFPNASDAQ:TRVN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$5.10+1.0%$5.74$4.08▼$6.53$293.10M1.0423,461 shs7,991 shsKZRKezar Life Sciences$0.82+3.8%$0.89$0.67▼$3.13$59.84M0.47700,056 shs709,448 shsORMPOramed Pharmaceuticals$2.33+2.6%$2.89$1.67▼$5.25$94.41M1.81169,887 shs59,020 shsTFFPTFF Pharmaceuticals$2.58-17.0%$6.17$2.51▼$21.25$6.50M1.2928,123 shs47,251 shsTRVNTrevena$0.37+5.7%$0.50$0.30▼$3.28$6.78M1.1183,771 shs423,653 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada+0.99%-0.58%-10.99%-9.41%+12.09%KZRKezar Life Sciences+4.05%+1.54%-15.65%+0.24%-66.99%ORMPOramed Pharmaceuticals+2.64%-3.72%-19.93%+1.75%+1.30%TFFPTFF Pharmaceuticals-17.04%-26.70%-66.45%-46.03%-84.20%TRVNTrevena+5.17%-5.42%-19.52%-45.02%-46.35%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKMDAKamada4.0094 of 5 stars3.55.00.00.01.91.73.1KZRKezar Life Sciences3.9029 of 5 stars3.22.00.04.61.91.71.3ORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals1.7178 of 5 stars3.53.00.00.02.40.00.6TRVNTrevena1.7325 of 5 stars3.53.00.00.02.50.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMDAKamada3.00Buy$11.00115.69% UpsideKZRKezar Life Sciences2.33Hold$11.001,238.20% UpsideORMPOramed PharmaceuticalsN/AN/AN/AN/ATFFPTFF Pharmaceuticals3.00Buy$72.002,690.70% UpsideTRVNTrevena3.00Buy$9.002,331.12% UpsideCurrent Analyst RatingsLatest TRVN, KZR, TFFP, ORMP, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/28/2024TFFPTFF PharmaceuticalsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $44.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/7/2024KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMDAKamada$142.52M2.06$0.43 per share11.84$4.25 per share1.20KZRKezar Life Sciences$7M8.55N/AN/A$2.58 per share0.32ORMPOramed Pharmaceuticals$1.34M70.46N/AN/A$4.04 per share0.58TFFPTFF Pharmaceuticals$730K8.91N/AN/A$4.04 per share0.64TRVNTrevena$3.12M2.17N/AN/A($0.44) per share-0.84Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMDAKamada$8.28M$0.1534.0012.44N/A5.81%5.66%3.57%5/22/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)ORMPOramed Pharmaceuticals$5.53M$0.1416.64∞N/AN/A-7.15%-5.70%5/9/2024 (Estimated)TFFPTFF Pharmaceuticals-$21.24M-$12.51N/AN/AN/A-2,897.95%-163.14%-144.77%5/9/2024 (Estimated)TRVNTrevena-$40.29M-$3.13N/AN/AN/AN/A-1,018.15%-98.93%5/20/2024 (Estimated)Latest TRVN, KZR, TFFP, ORMP, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023TFFPTFF Pharmaceuticals-$2.00-$2.01-$0.01-$2.01$0.20 million$0.11 million3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/A3/6/2024Q4 2023KMDAKamada$0.05$0.09+$0.04$0.09$37.71 million$36.43 million3/6/2024Q4 2023ORMPOramed Pharmaceuticals-$0.12-$0.08+$0.04-$0.49N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKMDAKamadaN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMDAKamadaN/A3.431.64KZRKezar Life Sciences0.0511.6611.66ORMPOramed PharmaceuticalsN/A3.063.06TFFPTFF PharmaceuticalsN/A3.123.12TRVNTrevena8.354.664.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMDAKamada20.38%KZRKezar Life Sciences67.90%ORMPOramed Pharmaceuticals12.73%TFFPTFF Pharmaceuticals15.25%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipKMDAKamada36.10%KZRKezar Life Sciences7.90%ORMPOramed Pharmaceuticals12.00%TFFPTFF Pharmaceuticals5.60%TRVNTrevena2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKMDAKamada37857.47 million36.73 millionOptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableORMPOramed Pharmaceuticals1240.52 million35.66 millionOptionableTFFPTFF Pharmaceuticals192.52 million2.38 millionOptionableTRVNTrevena2318.32 million17.88 millionOptionableTRVN, KZR, TFFP, ORMP, and KMDA HeadlinesSourceHeadlineTrevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 22 at 2:16 AMTrevena Cross free art exhibition featuring local artistsmsn.com - April 21 at 8:56 PMTrevena gets grant for pharmaceutical composition for modulating S1P1 receptor activitypharmaceutical-technology.com - April 18 at 8:34 AMTrevena (TRVN) Price Target Decreased by 7.69% to 6.12msn.com - April 18 at 3:33 AMTrevena (NASDAQ:TRVN) Now Covered by StockNews.comamericanbankingnews.com - April 14 at 2:16 AMTrevena Inc TRVNmorningstar.com - April 5 at 11:56 PMDanny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In Bulgariamsn.com - April 4 at 2:44 AMTrevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital Environmentmsn.com - April 3 at 3:48 AMRecap: Trevena Q4 Earningsbenzinga.com - April 2 at 2:41 AMTrevena Reports Fourth Quarter 2023 Results and Provides Corporate Updateglobenewswire.com - April 1 at 7:00 AMTrevena gets grant for pharmaceutical process for preparing compound of formula (i)pharmaceutical-technology.com - March 28 at 10:37 AMTrevena files patent for treatment of acute respiratory distress syndrome using specific peptidespharmaceutical-technology.com - March 22 at 9:37 PMTrevena Cross cafe reopening as the Palm Tree Bistromsn.com - March 16 at 3:06 PMTrevena Cross Garden Centre, The Palm Tree Bistrofalmouthpacket.co.uk - March 14 at 1:26 PMThe Palm Tree Bistro at Trevena Cross Nurseries reopeningmsn.com - March 8 at 10:03 AMTrevena Stock (NASDAQ:TRVN), Short Interest Reportbenzinga.com - February 22 at 1:18 PMTrevena files to sell 2.78M shares for holdersmsn.com - January 10 at 7:29 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 8:45 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 3:44 PMTrevena announces private placement and warrant exercisemsn.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisemarkets.businessinsider.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 27 at 1:16 PMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’msn.com - December 16 at 1:50 AMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'msn.com - December 15 at 8:50 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsKamadaNASDAQ:KMDAKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Oramed PharmaceuticalsNASDAQ:ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.TFF PharmaceuticalsNASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.